Contributions
Stay tuned—this is where the team’s scientific contributions will be shared.
Accolades
Check back soon to see how this team is being recognized.
Data from our Team suggest that recombinant products from alpha-synuclein seeding-amplification assays (SAAs) may harbor an untapped wealth of conformational heterogeneity, echoing post translational modifications and conformational properties of seeds and assemblies in the brain, associated with different endophenotypes in Parkinson’s disease and related Lewy body diseases. In our Team approach, we will harness the latest breakthroughs in cryo-EM and mass spectrometry to provide an unprecedented vantage into specific seeds, co-factors, and pathologies to enable the rapid development of scalable conformation-specific precision SAAs that accurately predict important endophenotypes in disease and provide new targets for therapeutic intervention.
Leadership
Andrew West
Lead PI (Core Leadership)
Alberto Bartesaghi
Co-PI (Core Leadership)
Mario Borgnia
Co-PI (Core Leadership)
Lenora Higginbotham
Co-PI (Core Leadership)
Laura Volpicelli-Daley
Co-PI (Core Leadership)
Tuyana Malankhanova
Project Manager
Elizabeth Viverette
Project Manager
David Bradway
Data Manager
Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.